TDDC, Northwestern Medicine and Curant Health Collaborate on New Research Study
The purpose of this study is to assess the effectiveness of providing study drug infliximab for Crohn’s disease (CD) and ulcerative colitis (UC). Infliximab is an example of a certain class of medications used to treat CD and UC by making changes to our body’s immune system.
Participants in this study will receive telephone calls by Curant Health, a health management pharmacy company that is partnering with the study team to help ensure patients understand and take prescribed medications and monitor for development of any side-effects to new medications.
These calls will be made during weeks 0, 2 and 6. These calls will take 10-15 minutes.
In addition to the care coordination we will provide for this study
Curant Health offers personalized medication management:
- Custom bubble packaging based on your medication regimen
- Free delivery of medication to your home or other preferred address
We are asking you to take part in this research study because you have a diagnosis of either Crohn’s disease (CD) or Ulcerative colitis (UC) and you are about to be started on infliximab therapy. This document has important information about the reason for the study, what you will do if you choose to be in this research study, and the way we would like to use information about you and your health.
You can choose not to participate in the study or leave it at any time.
Need to contact us?
If you would like to enroll now or learn more about this program, please give us a call. A Curant Health clinical pharmacist will be happy to review the benefits and details of this study with you.
Call us at 866-437-8040 ext. 309
Monday – Friday, 8:30 – 5:30 Eastern Time